An assessment of nucleic acid amplification testing for active mycobacterial infection

Literature search for utility weights in TB

Tuberculosis AND (quality of life OR utility OR EQ-5D OR euroqol OR time trade off OR standard gamble OR visual analogue scale OR VAS OR SF-36 OR SF-6D OR SF 6D OR SF 36 OR EQ 5D)

Database	Last updated
PubMed	15 August 2014

Appendix Additional information relating to the economic evaluation

Amikacin administration costs

Table Amikacin administration costs

-	False-positive MDR-TB	True MDR-TB
Average administrations per week	5	4
Weeks treated	8.7	26.1
Total amikacin administrations	43.5	104.4
In-patient administrations	9.3	14.9
Outpatient administrations	34.2	89.5
Cost of outpatient administration	$234	$234
Total administration costs	$8,002	$20,943

MDR-TB = multidrug-resistant tuberculosis

Utility values

Table Utility values identified in studies that elicit utilities in a TB population

Study	Utility weight	Comments
Winetsky et al. (2012)	No TB / recovered 1.00 Active TB ± MDR, undiagnosed 0.73 Active TB ± MDR, AFB treated 0.68 Active TB ± MDR, AFB+ treated 0.60	Former Soviet Union prison inmates—unclear how preferences were elicited
Kittikraisak et al. (2012)	TB (treated) 0.65 MDR-TB (treated) 0.49 Cured TB ± MDR 0.89 HIV (no TB) 0.75 HIV with TB (treated) 0.62 Cured TB ± MDR with HIV 0.88	Thai patients diagnosed with TB (including those on treatment and those who had completed treatment) and/or HIV EQ-5D weights adjusted for age and monthly household income (also presents unadjusted weights with standard error)
Awaisu et al. (2012)	At baseline 0.70 At 3 months treatment 0.87 At 6 months treatment 0.91	Malaysian smokers newly diagnosed with TB EQ-5D weights for control group (treatment administered by DOTS)
Kruijshaar et al. (2010) (reported in Jit et al. (2011))	Untreated TB 0.68 After 2 months treatment 0.81	UK patients diagnosed with active TB were administered generic health-related quality-of-life questionnaires (EQ-5D and SF-36) at diagnosis and 2 months into therapy. The median time between questionnaires was 73 days (IQR: 54-104) Overall scores are not reported in Krujisharr et al. (2010), but are reported in Jit et al. (2011)
Babikako et al. (2010)	At baseline 0.607 At 2 months treatment 0.671 At 8 months treatment 0.785	Ugandan patients with known HIV status and TB enrolled based on duration of TB therapy: started at 2 months and completed at 8 months
Guo et al. (2008)	Active TB (treated) 0.68 (0.65–0.72) By severity of TB symptoms: Very mild 0.84 (0.11) Mild 0.68 (0.05) Moderate 0.64 (0.10) Severe 0.59 (0.15) Very severe 0.54 (0.08)	Canadian patients with recent diagnosis of active TB (within 2 months) Measure using the SF-6D (also HUI2, HUI3 and VAS) Also reports by self-reported symptom control

AFB = acid-fast bacilli; DOTS = directly observed treatment, short-course; HIV = human immunodeficiency virus; IQR = inter-quartile range; MDR = multidrug-resistant; MDR-TB = multidrug-resistant tuberculosis; TB = tuberculosis; VAS = visual analogue scale